We are live on ! Find out more
AL

Aspiriant LLC Portfolio holdings

AUM $3.51B
1-Year Est. Return 13.98%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+13.98%
3 Year Est. Return
+39.43%
5 Year Est. Return
+43.32%
10 Year Est. Return
+133.07%
AUM
$1.17B
AUM Growth
+$69.9M
Cap. Flow
-$123M
Cap. Flow %
-10.45%
Top 10 Hldgs %
45.17%
Holding
233
New
50
Increased
46
Reduced
102
Closed
21

Sector Composition

Rank Sector Weight
1 Financials 4.56%
2 Technology 3.54%
3 Communication Services 2.54%
4 Healthcare 2.13%
5 Industrials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VBR icon
226
Vanguard Small-Cap Value ETF
VBR
$37.1B
-2,117
Closed -$256K
VCR icon
227
Vanguard Consumer Discretionary ETF
VCR
$6.15B
-2,505
Closed -$322K
VPU
228
Vanguard Utilities ETF
VPU
$8.64B
-2,086
Closed -$223K
POT
229
DELISTED
Potash Corp Of Saskatchewan
POT
-10,940
Closed -$198K
DD
230
DELISTED
Du Pont De Nemours E I
DD
-4,551
Closed -$334K
SE
231
DELISTED
Spectra Energy Corp Wi
SE
-51,570
Closed -$2.12M
GSP
232
DELISTED
Barclays Bank PLC iPath Exchange Traded Notes due 2036 Linked to GSCI Total Return Index
GSP
-32,315
Closed -$474K
GSC
233
DELISTED
GS Connect S&P GSCI Enhanced Commodity Total Return Strategy Index ETN (maturity subject to postpone
GSC
-50,597
Closed -$1.18M

Similar funds

Aspiriant LLC's Q1 2017 Portfolio in Review

As of Q1 2017, Aspiriant LLC held 233 positions worth $1.17B, up 6.3% from $1.1B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Aspiriant LLC withdrew a net $123M in Q1 2017, closing 21 positions and reducing 102 holdings. Its most notable exit was VanEck Biotech ETF, an estimated $2.5M position sold in full.

By sector, the portfolio is most concentrated in Financials at 4.6% of assets, down from 5.1% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Aspiriant LLC opened a new position in Vanguard Short-Term Corporate Bond ETF worth $19.1M.

  • Aspiriant LLC's largest Q1 2017 buy was Vanguard Short-Term Corporate Bond ETF: 240,133 shares worth $19.1M.
  • Aspiriant LLC added most to Vanguard S&P 500 ETF in Q1 2017, an estimated $30.7M increase.
  • Aspiriant LLC's biggest Q1 2017 reduction was Berkshire Hathaway Class A, cutting an estimated $124M.
  • Aspiriant LLC fully exited VanEck Biotech ETF in Q1 2017, selling an estimated $2.5M.
  • Aspiriant LLC's ten largest holdings make up 45% of its $1.17B portfolio in Q1 2017.
  • Aspiriant LLC opened 50 new positions and closed 21 in Q1 2017.
  • Aspiriant LLC's portfolio value rose 6.3% quarter-over-quarter to $1.17B.

Based on Aspiriant LLC's 13F filing for Q1 2017, filed 15 May 2017.